(iii) Blood glucose, lipid profile, and glomerular filtration rate calculation
(iv) Cardiovascular global risk assessment using guidelines
(v) Transthoracic echocardiogram (TTE), including measurements of LVEF (ideally 3D but at least 2D) and GLS; in the absence of GLS quantification of LV longitudinal function, use mitral annular displacement by M-mode echocardiography and/or peak systolic velocity of the mitral annulus by pulsed-wave DTI
(vi) LV contrast agents could be potentially useful in 2D echocardiography
(vii) Cardiac magnetic resonance is recommended if the quality of TTE is suboptimal
(viii) Use the same imaging modality for monitoring
(ix) Actively manage modifiable cardiovascular risk factors and diseases
(x) Encourage exercise on a regular basis and healthy dietary habits
